evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,730 questions · 18,059 findings · 1,282 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4,360 · 24.1%GRADE not reported 2,529 · 14%Very low 4,641 · 25.7%Low 4,007 · 22.2%Moderate 2,057 · 11.4%High 465 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Monthly pegloticase vs placebo

Serum urate normalisation ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Total adverse events · participants with tophi in gout

Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Lesinurad 200 mg plus allopurinol vs placebo plus allopurinol

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).

1 finding from 1 review

Lesinurad 400 mg plus allopurinol vs placebo plus allopurinol

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).

1 finding from 1 review

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

1 finding from 1 review

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Withdrawals due to adverse events · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

1 finding from 1 review

Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS

Proportion with complete resolution of a target tophus · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).

1 finding from 1 review

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review